- TRADE NAME: Scemblix (Novartis)
- INDICATIONS:
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors.
- CLASS: Kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 6–9 hours
- FDA APPROVAL DATE: 10/29/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inhibitors, Imatinib, Itraconazole oral solution containing hydroxypropyl-β-cyclodextrin - PREGNANCY: Based on findings from animal studies, asciminib can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective contraception during treatment with asciminib and for one week after the last dose.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 11/14/2024
